Search results
Added:
1 year ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical…
View more
Added:
1 year ago
ESC 2024 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, US) for a concise and insightful summary of the hot-line and late-breaking data that is expected to have an impact on heart failure care.Trials covered in detail include:FINEARTS HFHELIOS-BRESHAPE-HF2Recorded on-site at ESC Congress 2024, London.Editors: Jordan Rance and Mirjam Boros…
View more
Added:
1 month ago
Dr Harriette Van Spall (McMaster University, CA) hosts this Masterclass on the contemporary management of heart failure with preserved and mildly reduced ejection fraction, joined by Professor Maja Čikeš (University Hospital Centre Zagreb, HR) for a focused review of the datasets that are redefining treatment in HFpEF/HFmrEF. Framed around the transition from a field once dominated by therapeutic…
View more
Added:
8 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in…
View more
Added:
3 months ago
ACC 2026 — Dr Deepak Bhatt (Mount Sinai Fuster Heart Hospital, US) delivers his expert verdict on three late-breaking clinical trials from ACC 2026 that are poised to influence cardiovascular care and future clinical guidelines.Dr Bhatt highlights data updates from the SURPASS-CVOT trial, exploring expanded cardiometabolic findings with tirzepatide versus dulaglutide, discusses the HI-PEITHO…
View more
Added:
9 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in…
View more
Added:
1 month ago
HFA Congress 2026 - Dr Kevin Damman (University Medical Centre Groningen, Groningen, NL) joins us to discuss findings from a study-level meta-analysis combining data from the DECISION, DIGIT-HF and DIG trials to evaluate the role of digitalis glycosides (digoxin and digitoxin) in heart failure with reduced and mildly reduced ejection fraction.This analysis brings together evidence from three…
View more
Added:
1 month ago
Dr Marat Fudim (Duke University School of Medicine, Durham, NC, US) joins us to discuss congestion phenotypes in heart failure, the distinction between true volume overload and maladaptive volume redistribution, and the emerging role of greater splanchnic nerve modulation.In this interview, Dr Fudim explores one of the most clinically nuanced challenges in heart failure management:…
View more
Added:
7 months ago
Explore the diagnostic and therapeutic complexities of cardiac sarcoidosis with Prof Emer Joyce.This presentation, part of the comprehensive Cardiomyopathies track, tackles the persistent challenges in cardiac sarcoidosis, emphasizing that despite decades of clinical experience, diagnosis remains the field's greatest hurdle.Prof Joyce explores the heterogeneous clinical phenotypes capable of…
View more
Added:
1 month ago
HFA Congress 2026 — Dr Ambarish Pandey (University of Texas Southwestern Medical Center, Texas, US) joins us to discuss findings on diuretic resistance drawn from TRANSFORM-HF, a large-scale, pragmatic, randomised clinical effectiveness trial comparing torsemide versus furosemide in patients hospitalised with heart failure.TRANSFORM-HF enrolled 2,973 patients across 60 US sites, randomising 1:1…
View more